AIM Breakfasts

AIM BREAKFAST – 31st August 2016

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 1,006

Total number of AIM Companies trading: 993*
* As at 30 August 2016

Dish of the Day:

No AIM Joiners today

Off the Menu:

Superglass Holdings  (SPGH.L) to delist later this month  following cash offer by Inflection Management Corp 

Set Menu ISDX Growth:

Total number of ISDX Growth Market Companies (Incl Susp): *

Total number of ISDX Growth Market Companies trading: *
* As at 30 August 2016

Dish of the Day:

Off the Menu:

What’s Cooking in the IPO Kitchen?

Misys— The press reports that the Banking Technology provider owned by Vista Equity Partners is seeking a £5.5bn float in London

Bacanora Lithium— To list on AIM around 28 Sep as holding company for TSX listed Bacanora Minerals at £100m market cap

Aura Energy—ASX listed uranium developer (ASX:AEE) expected to join AIM 6 September

Breakfast Buffet

Crossword Cybersecurity* (ISDX:CCS) 192p £4.6m

The ISDX listed technology commercialisation company focusing exclusively on the cyber security sector announced the appointment of Sir Richard Dearlove KCMG OBE as Non-Executive Chairman. He brings to the Board unparalleled experience across government, education & global business. He joined MI6 in 1966 undertaking various overseas & head office roles before promotion to Chief of the Secret Intelligence Service in 1999, which he left in 2004. Tom Ilube remains as CEO.

Goldplat (GDP.L) 6p £10.05m

The African gold producer announced a positive operations update for the three months ended 30 June 2016  reporting a total gold and gold equivalent production of 11,969 ounces, continued profitability and steady progress on priority capital projects.

During the Quarter, the Rand Refinery silver toll recovery project was completed and although the contract is currently under dispute, the Directors are confident that the dispute will be resolved.

Benchmark Holdings (BMK.L) 63p £328.45m

Benchmark announced that its Animal Health division has entered into an agreement with Evax AG, a Swiss equine biotech company, to develop a recombinant vaccine to prevent and treat the most prevalent skin disease in horses, Sweet Itch, also known as Insect Bite Hypersensitivity (IBH).  The estimated total market value for treatment of the disease is over £100 million per annum. Under the terms of the agreement, Benchmark will pay total consideration of £1.12m and is contributing up to a further £4m over the next 4 years .

FairFX Group (FFX.L) 30p £30.9m

The FinTech low-cost currency provider, is partnering with VizEat, Europe’s largest social dining network.  The agreement is designed to offer customers access to unique travel experiences while getting the best value for money when they are overseas. Aligning with FairFX’s core values, VizEat customers can benefit from preferential exchange rates, FairFX prepaid currency card offers and travel money expertise.  Since being founded in 2014, VizEat has 90,000 members from more than 100 countries .

Arria NLG (NLG.L) 14p £17.3m

Arria NLG, a technology leader in Natural Language Generation, has announced the public beta launch of Recount, a Software as a Service business reporting tool designed to work with large online accounting systems such as Xero, Quickbooks and Sage, providing customers with instant financial insights, expressed in plain language.  Recount has been integrated into Xero’s offerings for release in Australia and New Zealand, and will be available for Xero and Quickbooks in the USA by December, with more integration partners to come.

Quantum Pharma (QP.L) 89.5p £111.87m

H1 Jul 2016 update from the service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors. Trading for the period was in line with management expectations. Since the period end, Quantum has launched a Glycopyrronium Bromide 1mg/5ml Oral Solution for the treatment of peptic ulcers.  This is significant in illustrating the deliverability of the Group’s strategy of converting unlicensed to licensed products. FY2017E revs of £10.9m and EPS of 6.84p. Div 1.8p.

Taptica International (TAP.L) 128p £80m

The global end-to-end mobile advertising platform for advertising agencies and brands, announced its interim results for the six months ended 30 June 2016.  Revenues increased by 53% to $51.8m. Adjusted EBITDA of $9.2m ($2.8m). Declared special dividend of $0.0579 per share.  Momentum achieved in H1 has been sustained into the second half of 2016. Campaigns agreed with new Tier 1 clients, such as Cartoon Network, ABC and Zappos, are expected to deliver solid revenues in H2 2016. 8.3x PE.

Hummingbird Resources (HUM.L) 24p £82.4m

Hummingbird has announced the final results of a 14 month hydro-electric power  Pre-Feasibility Study  near Hummingbird’s 4.2Moz Dugbe Gold Project. The PFS, which was funded by IFC InfraVentures and carried out by Knight Piésold, confirms the potential viability of a range of options for HEP plants with the ability to supply a sustainable source of power for Dugbe, as well as the southeast Liberian region.  Importantly, the HEP plant also offers the potential to reduce the all in sustaining costs of  Dugbe.

Surgical Innovations Group (SUN.L) 2.62p £12.8m.

Much improved interim results for HYJun2016 from the designer and manufacturer of innovative medical technology for minimally invasive surgery,  showing robust growth, a return to profit and a return to a net cash bank position. Revenue up 16.9% to £3.04m. Net profit of £0.25m from £2m loss.  H2 revenues  have continued to outperform the corresponding period last year, and indications of customer demand for the remainder of 2016 are satisfactory.

Eurasia Mining (EUA.L) 0.58p £8.2m

The Russia focused PGM and gold production and development company,  working in partnership with Metal Tiger (MTR.L), has updated on work on the Semenovsky Tailings Project, in Bashkiria, Russia. Reserves report approved.  2.99 million tonnes of ore grading 1.18 g/t gold and 16.44 g/t of silver, with contained metal calculated as 3.5 tonnes of gold and 49.3 tonnes of silver.  The exclusivity option has also been extended to 15 November 2016.

Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email with “unsubscribe me”.